BioAtla, Inc. (BCAB): Depreciation & Amortization
$373.0K
Year ended 2025-12-31
$195.0K
Trailing 12 months to 2026-06-30
-32.2%
3-year compound annual growth
-18.0%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $373.0K | -59.7% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $925.0K | -24.2% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $1.22M | +1.8% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $1.20M | -9.8% | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | $1.33M | +31.9% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $1.01M | +17.2% | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | $860.0K | n/a | 2022-02-28, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | 2025-12-31 | $373.0K | -59.7% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.42M | -13.8% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $117.1K | +2.8% |
| Curis Inc (CRIS) | 2025-12-31 | $169.0K | -16.7% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $2.12M | -58.1% |
| Calidi Biotherapeutics, Inc. (CLDI) | 2025-12-31 | $1.65M | +7.6% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2024-12-31 | $56.0K | 0.0% |
| Pluri Inc. (PLUR) | 2026-06-30 | $511.0K | +61.7% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $215.0K | -19.2% |
Compare BCAB, SCNI, OTLK, CRIS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗